| dc.contributor.author | Dellinger, Ryan W. | |
| dc.contributor.author | Santos, Santiago Roel | |
| dc.contributor.author | Morris, Mark | |
| dc.contributor.author | Evans, Mal | |
| dc.contributor.author | Alminana, Dan | |
| dc.contributor.author | Marcotulli, Eric | |
| dc.contributor.author | Guarente, Leonard Pershing | |
| dc.date.accessioned | 2018-06-19T19:03:41Z | |
| dc.date.available | 2018-06-19T19:03:41Z | |
| dc.date.issued | 2017-11 | |
| dc.date.submitted | 2017-10 | |
| dc.identifier.issn | 2056-3973 | |
| dc.identifier.uri | http://hdl.handle.net/1721.1/116430 | |
| dc.description.abstract | NRPT is a combination of nicotinamide riboside (NR), a nicotinamide adenine dinucleotide (NAD⁺) precursor vitamin found in milk, and pterostilbene (PT), a polyphenol found in blueberries. Here, we report this first-in-humans clinical trial designed to assess the safety and efficacy of a repeat dose of NRPT (commercially known as Basis). NRPT was evaluated in a randomized, double-blind, and placebo-controlled study in a population of 120 healthy adults between the ages of 60 and 80 years. The study consisted of three treatment arms: placebo, recommended dose of NRPT (NRPT 1X), and double dose of NRPT (NRPT 2X). All subjects took their blinded supplement daily for eight weeks. Analysis of NAD⁺ in whole blood demonstrated that NRPT significantly increases the concentration of NAD⁺ in a dose-dependent manner. NAD⁺ levels increased by approximately 40% in the NRPT 1X group and approximately 90% in the NRPT 2X group after 4 weeks as compared to placebo and baseline. Furthermore, this significant increase in NAD⁺ levels was sustained throughout the entire 8-week trial. NAD⁺ levels did not increase for the placebo group during the trial. No serious adverse events were reported in this study. This study shows that a repeat dose of NRPT is a safe and effective way to increase NAD⁺ levels sustainably. | en_US |
| dc.publisher | Springer Nature | en_US |
| dc.relation.isversionof | http://dx.doi.org/10.1038/S41514-017-0016-9 | en_US |
| dc.rights | Creative Commons Attribution 4.0 International License | en_US |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
| dc.source | Nature | en_US |
| dc.title | Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study | en_US |
| dc.type | Article | en_US |
| dc.identifier.citation | Dellinger, Ryan W. et al. “Repeat Dose NRPT (nicotinamide Riboside and Pterostilbene) Increases NAD+ Levels in Humans Safely and Sustainably: a Randomized, Double-Blind, Placebo-Controlled Study.” Npj Aging and Mechanisms of Disease 3, 1 (November 2017): 17 © 2017 The Author(s) | en_US |
| dc.contributor.department | Massachusetts Institute of Technology. Department of Biology | en_US |
| dc.contributor.mitauthor | Guarente, Leonard Pershing | |
| dc.relation.journal | npj Aging and Mechanisms of Disease | en_US |
| dc.eprint.version | Final published version | en_US |
| dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
| eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
| dc.date.updated | 2018-06-19T12:54:40Z | |
| dspace.orderedauthors | Dellinger, Ryan W.; Santos, Santiago Roel; Morris, Mark; Evans, Mal; Alminana, Dan; Guarente, Leonard; Marcotulli, Eric | en_US |
| dspace.embargo.terms | N | en_US |
| dc.identifier.orcid | https://orcid.org/0000-0003-4064-2510 | |
| mit.license | PUBLISHER_CC | en_US |